Drug interactions involving antiepileptic drugs: Assessment of the consistency among three drug compendia and FDA-approved labels

Epilepsy and Behavior

Volumn 44, Issue , 2015, Pages 218-224

  Ekstein, Dana ^a   Tirosh, Matanya ^b   Eyal, Yonatan ^c   Eyal, Sara ^b,d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MYERS JDC BROOKDALE INSTITUTE   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic drugs; Compendia; Cytochrome P450; Drug information; Drug interactions

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; CYTOCHROME P450;

ARTICLE; CLINICAL PHARMACOLOGY; DOCUMENTATION; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG INTERACTION COMPENDIA; FOOD AND DRUG ADMINISTRATION; ADVERSE DRUG REACTION; DRUG DATABASE; DRUG EFFECTS; DRUG INTERACTION; DRUG LABELING; HUMAN; STANDARDS; UNITED STATES;

ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, PHARMACEUTICAL; DRUG INTERACTIONS; DRUG LABELING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84924542325     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.02.009     Document Type: Article

References (37)

1. Gidal B.E., French J.A., Grossman P., Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009, 72:419-425.
2. Landmark C.J., Fossmark H., Larsson P.G., Rytter E., Johannessen S.I. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011, 95:51-59.
3. Johannessen-Landmark C.J., Rytter E., Johannessen S.I. Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 2007, 16:356-364.
4. Nicholas J.M., Ridsdale L., Richardson M.P., Ashworth M., Gulliford M.C. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database. Seizure 2012, 21:466-470.
5. Tsiropoulos I., Gichangi A., Andersen M., Bjerrum L., Gaist D., Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 2006, 113:405-411.
6. Alexandre V., Capovilla G., Fattore C., Franco V., Gambardella A., Guerrini R., et al. Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. Epilepsia 2010, 921-925.
7. Eyal S., Rasaby S., Ekstein D. Concomitant therapy in people with epilepsy: potential drug-drug interactions and patient awareness. Epilepsy Behav 2013, 31:369-376.
8. Mintzer S., Maio V., Foley K. Use of antiepileptic drugs and lipid-lowering agents in the United States. Epilepsy Behav 2014, 34:105-108.
9. Karouni M., Henning O., Larsson P.G., Johannessen S.I., Johannessen Landmark C. Pharmacological treatment of psychiatric comorbidity in patients with refractory epilepsy. Epilepsy Behav 2013, 29:77-81.
10. Anderson G.D. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998, 32:554-563.
11. Brodie M.J., Mintzer S., Pack A.M., Gidal B.E., Vecht C.J., Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia 2012, 54:11-27.
12. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) - part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013, 52:927-966.
13. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) - part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013, 52:1045-1061.
14. Romo M.L., Carpio A., Kelvin E.A. Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?. J Clin Pharmacol 2014, 54:361-367.
15. Anthony M., Romero K., Malone D.C., Hines L.E., Higgins L., Woosley R.L. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 2009, 86:425-429.
16. Olvey E.L., Clauschee S., Malone D.C. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 2010, 87:48-51.
17. Vitry A.I. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007, 63:709-714.
18. Wong C.M., Ko Y., Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 2008, 42:1737-1748.
19. Guo J.J., Wigle P.R., Lammers K., Vu O. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Social Adm Pharm 2005, 1:460-479.
20. Micromedex® Healthcare Series [Drug Interactions] 2001, Thomson Micromedex, Published, Greenwood Village, Colo, URL: http://www.micromedexsolutions.com/home/dispatch. Updated periodically.
21. Clinical Pharmacology [Drug Interactions]. 2006, Published, Gold Standard, Inc., Tampa, FL, URL: https://www.clinicalpharmacology.com/. Updated Periodically.
22. Lexicomp Online®, Lexi-Interact® 2004, Published, Lexi-Comp, Inc., Hudson, Ohio, URL: http://www.uptodate.com/crlsql/interact/frameset.jsp. Updated periodically.
23. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004, 61:380-385.
24. Knollmann B.C., Smyth B.J., Garnett C.E., Salesiotis A.N., Gvozdjan D.M., Berry N.S., et al. Personal digital assistant-based drug reference software as tools to improve rational prescribing: benchmark criteria and performance. Clin Pharmacol Ther 2005, 78:7-18.
25. Centers for Medicare & Medicaid Services Last accessed 10/24/2014. http://www.cms.gov/Medicare/Coverage/CoverageGenInfo/compendia.html.
26. Löscher W., Klitgaard H., Twyman R.E., Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013, 12:757-776.
27. Patsalos P.N., Bourgeois B.F.D. The Epilepsy Prescriber's Guide to Antiepileptic Drugs 2013, Cambridge University Press, Cambridge, UK. 2nd ed.
28. Graham G.G., Punt J., Arora M., Day R.O., Doogue M.P., Duong J.K., et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011, 50:81-98.
29. Pentikäinen P., Neuvonen P., Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979, 16:195-202.
30. Golightly L.K., Drayna C.C., McDermott M.T. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012, 51:501-514.
31. Sanofi-Aventis. Rifadin (rifampin) product monograph, Revised 02/2013. Sanofi-Aventis, Quebec, Canada.
32. Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010, 10:119-140.
33. Härtter S., Sennewald R., Nehmiz G., Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013, 75:1053-1062.
34. Härtter S., Koenen-Bergmann M., Sharma A., Nehmiz G., Lemke U., Timmer W., et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012, 74:490-500.
35. Giessmann T., May K., Modess C., Wegner D., Hecker U., Zschiesche M., et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004, 76:192-200.
36. Owen A., Goldring C., Morgan P., Park B.K., Pirmohamed M. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol 2006, 62:237-242.
37. McAuley J.W., Miller M.A., Klatte E., Shneker B.F. Patients with epilepsy's perception on community pharmacist's current and potential role in their care. Epilepsy Behav 2009, 14:141-145.